These stop-motion videos are super creative
These stop-motion videos are super creative
The "Global Critical Care Patient Monitoring Market, 2020" report has been added to ResearchAndMarkets.com's offering.
The current wave of coronavirus hasn’t spared many parts of the U.S., and the Midwest is getting hit harder than ever before.
David Fincher is notorious for making his actors perform scenes dozens of times.
Here are the latest COVID-19 infection rates across England.
Just think, clean, shiny floors no matter how dirty the kids get.
The deal will see GoCompare's chairman Sir Peter Wood pocket more than £40 million in cash.
Generator deals for Black Friday, featuring Generac, DuroMax, Champion and Honda portable generator savings
UnitedHealth Group (NYSE: UNH) will host its annual Investor Conference with analysts and institutional investors virtually on Tuesday, December 1, 2020, beginning at 9:00 a.m. ET. Senior leaders will discuss how the Company is leading in the development of the next generation health system, advancing health care quality and outcomes for people, improving patient and physician experiences and working to reduce the total cost of health care. Management will also provide an overview of the Company’s outlook for its growth priorities and performance for 2021. In conjunction with the Investor Conference, an updated view of financial performance for 2020 and the initial outlook for 2021 will be released on the morning of Tuesday, December 1st at approximately 6:30 a.m. ET.
The "Global Noise, Vibration and Harshness (NVH) Testing Market, Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.
Black Friday Away deals have landed, explore all the best Black Friday Away Luggage discounts listed below
Prince Harry discussed his wife Meghan Markle’s miscarriage with his family, and the royals were also aware that Meghan was writing Wednesday’s heartbreaking article about it in the New York Times ahead of publication, a source told The Daily Beast Wednesday.The source was unwilling to specify exactly who had and had not been told or when, however it is believed that Queen Elizabeth, Prince Charles and Prince William were all in the loop.The Daily Beast has approached the royals for comment. Meghan Markle: Miscarriage Shattered My Heart Into PiecesThe extraordinarily intimate article is a dramatic break with long-standing traditions of the royal family revealing almost nothing about their private lives.The only time on record where a senior royal has been so open about losing a baby came in 2001, when Sophie Wessex, the wife of Prince Edward, the queen’s youngest son, made a statement speaking of her sadness at losing her unborn baby after she was airlifted to hospital from her home. After her hospitalization became public, Sophie said: “I’m obviously very sad, but it was just not meant to be. But there will be other chances.”That brief and buttoned-up statement of almost 20 years ago could hardly be more different to Meghan’s deeply personal essay in the New York Times today, in which Meghan wrote of her and Harry’s agonizing pain and grief at losing their baby.Meghan described in harrowing terms suffering a violent cramp as she was going about her daily morning routines, while holding her baby son, Archie.“I knew, as I clutched my firstborn child, that I was losing my second,” Meghan wrote.The fact that both the miscarriage and Meghan’s article about it were discussed by the Sussexes and Harry’s family will be seen by many as a positive sign that relations between the couple and the royals may be better than has been assumed in recent months.However, it also marks a dramatic break for Harry and Meghan with the established way of doing things.In her new piece Meghan referenced her interview in Africa where journalist Tom Bradby famously asked her, “Are you OK?”Another part of that interview seemed just as relevant Wednesday morning.“I really tried to adopt this British sensibility of a ‘stiff upper lip’—I really tried, but I think that what that does internally is probably really damaging,” Meghan said at the time.Harry’s grandmother, Queen Elizabeth may never have discussed her private life in her 68-year reign, and no doubt has her own views about the advisability of Meghan’s revelation today.It is quite clear that this groundbreaking and unprecedented article means that Harry and Meghan are declaring that the days of saying the best way to cope with the travails of life is by keeping everything hidden away are well and truly gone.Read more at The Daily Beast.Get our top stories in your inbox every day. Sign up now!Daily Beast Membership: Beast Inside goes deeper on the stories that matter to you. Learn more.
Moderna announces the European Commission’s approval of advance purchase agreement for initial 80 million doses of mRNA vaccine against COVID-19
Timothy Brehmer, a married father, was jailed for 10 and a half years at Salisbury Crown Court last month over the death of Claire Parry.
Dublin, Nov. 25, 2020 (GLOBE NEWSWIRE) -- The "Global Veterinary Medicines Market 2019-2028" report has been added to ResearchAndMarkets.com's offering. According to this report, the global veterinary medicines market is predicted to progress at a CAGR of 4.11% during the projected period of 2019-2028.The rise in livestock production, surge in multiple medical conditions in animals, and growing pet ownership, are significant factors augmenting the growth of the veterinary medicines market worldwide. Additionally, the rising animal healthcare expenditure and increasing demand for veterinary specialization are other factors that open avenues for the studied market's future.However, adverse effects post-vaccination and an inadequate number of veterinaries, are significantly limiting the veterinary medicines market's progress on a large scale.The global veterinary medicines market covers the Asia-Pacific, North America, Latin America, Europe, and the Middle East and Africa regions.Asia-Pacific is expected to become the fastest-evolving market for veterinary medicines during the estimated period of 2019-2028. The region's market is mainly motivated by the high investments in research and development by global companies, along with the continual efforts for commercialization of veterinary pharmaceuticals and vaccines at a lower cost. Additionally, the crucial need to control the high incidence of zoonotic disease and manage disease outbreaks is likely to propel the APAC region's veterinary medicines market's development.The key companies involved in the market include Boehringer Ingelheim Animal Health GmbH, Indian Immunologicals Limited, Evonik Industries AG, Biogenesis Bago SA, Zoetis, Dechra Pharmaceuticals Plc, Neogen Corporation, Kindred Biosciences, Virbac SA, Ceva Sante Animale, Merck & Co, Vetoquinol, Archer Daniels Midland, Elanco, and Hester Biosciences Limited.Zoetis is known as one of the largest producers of medicines and vaccinations for pets as well as livestock. Its product portfolio includes vaccines, diagnostic products, genetic tests, biodevices, and services. The company offers its products for various species, such as cattle, fish, sheep, dogs, cats, and others. Moreover, it sells products to livestock producers, retail outlets, veterinarians, and third-party distributors. The company serves customers worldwide, with its headquarter in the United States. Key Topics Covered: 1. Global Veterinary Medicines Market - Summary2. Industry Outlook2.1. Market Definition2.2. Porter's Five Forces Model2.2.1. Threat of New Entrants2.2.2. Threat of Substitute Products2.2.3. Bargaining Power of Buyers2.2.4. Bargaining Power of Suppliers2.2.5. Threat of Competitive Rivalry2.3. Industry Components2.4. Legal Policy and Regulatory Framework2.5. Impact of Covid-19 on Veterinary Medicines Market2.6. Market Attractiveness Index2.7. Key Insight2.8. Market Drivers2.8.1. Rise in Livestock Production2.8.2. Surge in Various Medical Conditions in Animals2.8.3. Increasing Ownership of Pets2.9. Market Restraints2.9.1. Adverse Effects of Post-Vaccination2.9.2. Lack of Adequate Number of Veterinarians2.10. Market Opportunities2.10.1. Growing Animal Healthcare Expenditure2.10.2. Increasing Demand for Veterinary Specialization2.11. Market Challenges2.11.1. Stringent Regulations2.11.2. High Cost of Animal Vaccines3. Global Veterinary Medicines Market Outlook - by Animal Type3.1. Companion Animals3.2. Livestock Animals4. Global Veterinary Medicines Market Outlook - by Distribution Channel4.1. Retail Veterinary Pharmacies4.2. Veterinary Hospital Pharmacies5. Global Veterinary Medicines Market Outlook - by Route of Administration5.1. Parenteral Route5.2. Oral Route5.3. Topical Route6. Global Veterinary Medicines Market Outlook - by Product6.1. Drugs6.1.1. Anti-Infective6.1.2. Anti-Inflammatory6.1.3. Parasiticide6.2. Vaccines6.2.1. Inactivated Vaccines6.2.2. Attenuated Vaccines6.2.3. Recombinant Vaccines6.3. Medicated Feed Additives6.3.1. Antibiotics6.3.2. Amino Acids7. Geographical Analysis7.1. North America7.1.1. Market by Animal Type7.1.2. Market by Distribution Channel7.1.3. Market by Route of Administration7.1.4. Market by Product220.127.116.11. Market by Drugs Type18.104.22.168. Market by Vaccines Type22.214.171.124. Market by Medicated Feed Additives Type7.1.5. Country Analysis126.96.36.199. United States188.8.131.52. Canada7.2. Europe7.2.1. Market by Animal Type7.2.2. Market by Distribution Channel7.2.3. Market by Route of Administration7.2.4. Market by Product184.108.40.206. Market by Drugs Type220.127.116.11. Market by Vaccines Type18.104.22.168. Market by Medicated Feed Additives Type7.2.5. Country Analysis22.214.171.124. Germany126.96.36.199. France188.8.131.52. United Kingdom184.108.40.206. Italy220.127.116.11. Russia18.104.22.168. Spain22.214.171.124. Rest of Europe7.3. Asia-Pacific7.3.1. Market by Animal Type7.3.2. Market by Distribution Channel7.3.3. Market by Route of Administration7.3.4. Market by Product126.96.36.199. Market by Drugs Type188.8.131.52. Market by Vaccines Type184.108.40.206. Market by Medicated Feed Additives Type7.3.5. Country Analysis220.127.116.11. China18.104.22.168. Japan22.214.171.124. Australia & New Zealand126.96.36.199. India188.8.131.52. South Korea184.108.40.206. Asean Countries220.127.116.11. Rest of Asia-Pacific7.4. Latin America7.4.1. Market by Animal Type7.4.2. Market by Distribution Channel7.4.3. Market by Route of Administration7.4.4. Market by Product18.104.22.168. Market by Drugs Type22.214.171.124. Market by Vaccines Type126.96.36.199. Market by Medicated Feed Additives Type7.4.5. Country Analysis188.8.131.52. Brazil184.108.40.206. Mexico220.127.116.11. Rest of Latin America7.5. Middle East and Africa7.5.1. Market by Animal Type7.5.2. Market by Distribution Channel7.5.3. Market by Route of Administration7.5.4. Market by Product18.104.22.168. Market by Drugs Type22.214.171.124. Market by Vaccines Type126.96.36.199. Market by Medicated Feed Additives Type7.5.5. Country Analysis188.8.131.52. Saudi Arabia184.108.40.206. United Arab Emirates220.127.116.11. Turkey18.104.22.168. South Africa22.214.171.124. Rest of Middle East & Africa8. Company Profiles8.1. Evonik Industries AG (Rag Stiftung)8.2. Indian Immunologicals Limited8.3. Boehringer Ingelheim Animal Health GmbH8.4. Merck & Co8.5. Zoetis8.6. Biogenesis Bago Sa8.7. Vetoquinol (Soparfin Sca)8.8. Archer Daniels Midland8.9. Ceva Sante Animale8.10. Virbac Sa8.11. Dechra Pharmaceuticals plc8.12. Neogen Corporation8.13. Elanco8.14. Hester Biosciences Limited8.15. Kindred Biosciences9. Research Methodology & Scope9.1. Research Scope & Deliverables9.1.1. Objectives of Study9.1.2. Scope of Study9.2. Sources of Data9.2.1. Primary Data Sources9.2.2. Secondary Data Sources9.3. Research Methodology9.3.1. Evaluation of Proposed Market9.3.2. Identification of Data Sources9.3.3. Assessment of Market Determinants9.3.4. Data Collection9.3.5. Data Validation & Analysis For more information about this report visit https://www.researchandmarkets.com/r/jo4622 Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Lorraine Stanley discusses the festive episodes.
To distribute to Endesa, S.A. shareholders an interim dividend against FY 2020 profits in the amount of €0.70 gross per share. Payment of this dividend will be made, subject to the provisions of current tax regulations, from 4 January 2021 through Banco Santander, S.A., in accordance with the provisions in force for entities participating in Sociedad de Gestión de los Sistemas de Registro, Compensación y Liquidación de Valores, S.A., (IBERCLEAR). - Date from which the shares of Endesa, S.A. will be traded without the right to benefit from the dividend (ex-dividend date): 30 December 2020.
(Bloomberg) -- Global stocks paused amid their best monthly rally in three decades as a call for more bad-loan provisions depressed European banking shares. U.S. futures fluctuated before key economic data.The Stoxx Europe 600 Index edged lower, as cyclicals such as mining and energy firms fell, offsetting advances in defensives including utility shares. ABN Amro Bank NV and Commerzbank AG dropped more than 4% and led euro-area lenders lower after the European Central Bank said the industry will probably have to set aside more money to soak up losses when government pandemic support ends.Futures on the S&P 500 Index and Dow Jones Industrial Average wavered after the gauges closed at record highs on Tuesday. The caution came as U.S. economic data, from jobless claims to consumer confidence, were due before markets close and traders head off for the Thanksgiving holiday. A gauge of Asia-Pacific shares erased earlier 1.1% gain.Positive vaccine news and the formal start of President-elect Joe Biden’s transition to power -- including the selection of Janet Yellen as Treasury secretary -- have fueled optimism about the outlook for risk assets. At the same time, restrictions to curb surging coronavirus cases threaten to slow the world’s economic recovery. An MSCI gauge of global shares stalled on Wednesday after gaining 13% in November, still set for the best month since 1988.In addition to the U.S. economic data on Wednesday, traders will also be keeping an eye on minutes of the most recent Federal Open Market Committee meeting.“Now, there’s big event risk up ahead: FOMC minutes,” said Ilya Spivak, head Asia-Pacific strategist at DailyFX. “The worry is that the Fed will continue to signal that they’re keeping to a hands-off posture. No tightening, but no new easing either.”Elsewhere, oil held at about $45 a barrel in New York, and copper touched the highest since 2014. Bitcoin edged above $19,000.Here are some key events coming up:Minutes of the most recent Federal Open Market Committee meeting are due Wednesday.U.S. jobless claims, GDP and personal spending data come Wednesday.U.K. Chancellor of the Exchequer will lay out spending plan on Wednesday.Thursday sees a policy decision and briefing from the Bank of Korea.U.S. celebrates the Thanksgiving holiday on Thursday.The week ends with Black Friday, the traditional start of the U.S. holiday shopping season.These are the main moves in markets:StocksFutures on the S&P 500 Index dipped 0.1% as of 6:27 a.m. New York time.The Stoxx Europe 600 Index declined 0.3%.The MSCI Asia Pacific Index decreased 0.1%.The MSCI Emerging Market Index fell 0.5%.CurrenciesThe Bloomberg Dollar Spot Index gained 0.1%.The euro dipped 0.1% to $1.1883.The British pound declined 0.3% to $1.3316.The onshore yuan strengthened 0.2% to 6.577 per dollar.The Japanese yen weakened 0.1% to 104.50 per dollar.BondsThe yield on 10-year Treasuries declined one basis point to 0.87%.The yield on two-year Treasuries was unchanged at 0.16%.Germany’s 10-year yield fell one basis point to -0.58%.Britain’s 10-year yield declined two basis points to 0.309%.Japan’s 10-year yield dipped less than one basis point to 0.021%.CommoditiesWest Texas Intermediate crude gained 1% to $45.36 a barrel.Brent crude gained 1.2% to $48.42 a barrel.Gold strengthened 0.1% to $1,808.77 an ounce.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
The European Union wants faster procedures to produce generic versions of drugs without the consent of patent holders, an EU document says, in a move meant to bypass usual intellectual rights protections in exceptional circumstances. "The Commission sees the need to ensure that effective systems for issuing compulsory licences are in place, to be used as a means of last resort and a safety net, when all other efforts to make IP (intellectual property) available have failed," the document published on Wednesday said. The measure, if ever applied, would effectively allow EU states to produce generic drugs without the consent of the pharmaceutical companies that developed them and still own the intellectual property rights.
A gay staffer has been appointed to a powerful role by president-elect Joe Biden.
Award winners will be announced in December.